Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the CALGB 40603 trial that examined the neoadjuvant treatment of triple-negative breast cancer (TNBC).

In the study, patients with TNBC were randomized to receive the neoadjuvant standard of care with or without carboplatin, a DNA damaging chemotherapy. By adding carboplatin to the standard of care, the rate of pathologic complete response (pCR) was improved, Arteaga says. Additionally, the rate of pCR in this study could translate into a long-term improvement in outcomes.

Videos

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Dr. Arteaga Discusses the CALGB 40603 Trial

Carlos L. Arteaga, MD, director of the Breast Cancer Program at the Vanderbilt-Ingram Cancer Center and the co-director of the San Antonio Breast Cancer Symposium (SABCS), describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

For practicing oncologists, who see patients five days a week, Arteaga hopes that SABCS will provide relevant information on new trends in breast cancer care. If patterns in care need revised, SABCS may provide essential information to induce skepticism and foster progress.

SABCS hopes to provide the latest information on targeted therapies in breast cancer, for clinical investigators. This information is vital for making enlightened decisions on future research, in the following year.

Arteaga hopes scientists will leave the symposium with a better understanding of the key questions in breast cancer biology. This meeting provides insight into clinically relevant areas that will likely benefit this group of individuals a great deal.

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

Carlos L. Arteaga, MD

Articles

Dr. Arteaga Discusses the CALGB 40603 Trial

Dr. Arteaga on Key Takeaway Points From the 2012 SABCS